Novavax (NVAX) stock dropped by 11.4% after a significant deal with Sanofi and the release of its Q3 results. Is this a sign of a major shift in the investment narrative? Let's dive in!
In November 2025, Novavax finalized the transfer of its U.S. marketing authorization for its COVID-19 vaccine to Sanofi. Simultaneously, the company reported its third-quarter results. These results included a revenue of US$70.45 million and a net loss of US$202.38 million for the quarter. However, the report also showed a net income of US$422.78 million for the nine months ending September 30, 2025.
This collaboration with Sanofi not only provided Novavax with a US$25 million milestone payment but also sets the stage for future revenue through milestones and royalties. This is based on product commercialization and future developments under the agreement.
We'll now examine how this completed transfer to Sanofi, along with the milestone payment, could reshape the investment narrative surrounding Novavax.
Did you know? These 13 companies thrived after the COVID-19 pandemic and have what it takes to survive potential economic challenges. Discover why before your portfolio feels any pressure.
Recapping the Novavax Investment Narrative
To be a Novavax shareholder today, you're essentially betting on the company's ability to generate revenue through partnerships, particularly with Sanofi. You also need to believe in their ability to manage the decreasing demand for standalone COVID-19 vaccines. The recent US$25 million milestone payment from Sanofi offers some short-term reassurance. However, the primary drivers remain the pace and success of Nuvaxovid's commercialization and the development of combination vaccines. The main risk continues to be the reliance on partners meeting their regulatory and market goals on time.
The most significant recent event is the November 2025 announcement, which finalized the transfer of Nuvaxovid's U.S. marketing authorization to Sanofi. This move triggers new financial inflows for Novavax. It also increases its dependence on the outcomes delivered by external partners. This directly links revenue stability to Sanofi's commercial performance in a highly competitive market. The future impact on Novavax will largely depend on...
Read the full narrative on Novavax (it's free!)
Novavax's current projections estimate a revenue of $348.5 million and earnings of $55.9 million by 2028. This would require a 31.4% annual revenue decline and a $366.9 million decrease in earnings from $422.8 million.
Discover how Novavax's forecasts yield a $13.11 fair value , which is a 76% upside to its current price.
Exploring Different Perspectives
Community members at Simply Wall St have offered 10 independent fair value targets for Novavax, ranging widely from US$4.30 to US$100 per share. While opinions vary, the increased reliance on partners like Sanofi remains a key factor for Novavax’s future growth and risk profile. Make sure to review several viewpoints before deciding where you stand.
Explore 10 other fair value estimates on Novavax - why the stock might be a potential multi-bagger!
Build Your Own Novavax Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the crowd.
- A great starting point for your Novavax research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
- Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Uncover the next big thing with financially sound penny stocks that balance risk and reward.
- Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Find companies with promising cash flow potential yet trading below their fair value.
Disclaimer: This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Novavax might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
What do you think about Novavax's future? Do you agree with the investment narrative, or do you have a different perspective? Share your thoughts in the comments below!
